高剂量超分割同步加量放疗对比标准剂量放疗治疗中国局限期小细胞肺癌:多中心开放标签随机3期试验
这项在中国16家公立医院开展的多中心、开放标签、随机3期试验,纳入224例18-70岁局限期小细胞肺癌患者,比较54 Gy与45 Gy胸部放疗(均30次、每日两次)联合化疗的疗效与安全性。
要点
- 两组3-4级放射性食管炎与放射性肺炎发生率相似,毒性可耐受
- 研究因独立数据安全监查委员会认定临床获益充分而提前终止
核心结论
- 对比标准剂量胸部放疗45 Gy,高剂量放疗54 Gy改善18-70岁局限期小细胞肺癌患者的总生存且未增加毒性。
- 结果支持将每日两次加速胸部放疗54 Gy联合化疗作为局限期小细胞肺癌一线治疗的替代选择。
研究设计与样本
- 开放标签、随机、3期试验,在中国16家公立医院开展,研究注册号NCT03214003。
- 2017年6月30日至2021年4月6日共入组224例患者,按1:1随机分配至54 Gy组(n=108)或45 Gy组(n=116)。
- 入组标准为18-70岁、组织学或细胞学证实局限期小细胞肺癌、ECOG评分0-1、既往未治疗或已接受一疗程顺铂或卡铂联合依托泊苷。
- 两组均接受容积调强弧形放疗(VMAT),每周10次每日两次胸部放疗,计划靶区均为45 Gy/30次;随机按ECOG评分、疾病分期、既往化疗疗程和化疗方案分层。
- 主要终点为意向治疗人群的总生存期,安全性在意向治疗(as-treated)人群中分析;中位随访46个月(IQR 33-56)。
主要发现
- 54 Gy组发生1例治疗相关死亡(心肌梗死)。
- 研究于2021年4月30日被独立数据安全监查委员会基于临床获益充分的证据提前终止。
关键数值与推荐
- 高剂量方案:54 Gy分30次,对大体肿瘤体积同步加量,每日两次,每周10次。
- 标准剂量方案:45 Gy分30次,每日两次,每周10次;两组计划靶区均为45 Gy分30次。
- 化疗方案为顺铂或卡铂联合依托泊苷;有效患者接受预防性颅脑放疗25 Gy分10次。
- 入组患者年龄18-70岁,ECOG体能状态评分0-1,中位年龄64岁(IQR 58-68),女性102例(46%)、男性122例(54%)。
临床怎么用
- 对18-70岁、ECOG 0-1的局限期小细胞肺癌患者,可考虑每日两次加速胸部放疗54 Gy同步加量联合化疗作为一线治疗。
- 采用该方案时需关注放射性食管炎和放射性肺炎,但本研究中3-4级发生率与标准剂量组相似。
- 有效患者按方案接受预防性颅脑放疗25 Gy分10次。
局限性
- 研究为中国16家公立医院开展,结果外推需考虑人群与地域差异。
- 研究因临床获益充分而提前终止。
- 开放标签设计,未设盲。
- 安全性在意向治疗(as-treated)人群分析,主要终点为意向治疗人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For the past 20 years, twice-daily thoracic radiotherapy with concurrent chemotherapy has been the treatment of choice for limited-stage small-cell lung cancer (LS-SCLC), which has a poor prognosis. We aimed to assess the efficacy and safety of high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) versus standard-dose radiotherapy (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC. METHODS: This open-label, randomised, phase 3 trial was performed at 16 public hospitals in China. The key inclusion criteria were patients aged 18-70 years, with histologically or cytologically confirmed LS-SCLC, who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and who were previously untreated or had received one course of cisplatin or carboplatin and etoposide. Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions to the gross tumour volume or VMAT with a simultaneous integrated boost of 54 Gy in 30 fractions to the gross tumour volume starting 0-42 days after the first chemotherapy course. Both groups received 10 fractions of twice-daily thoracic radiotherapy per week. The planning target volume was 45 Gy in 30 fractions in both groups. Patients with responsive disease received prophylactic cranial radiotherapy (25 Gy in 10 fractions). Randomisation was performed using a centralised interactive web response system, stratified by ECOG performance status, disease stage, previous chemotherapy course, and chemotherapy choice. The primary outcome was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This study was registered at ClinicalTrials.gov, NCT03214003. FINDINGS: From June 30, 2017, to April 6, 2021, 224 patients (102 [46%] females and 122 [54%] males; median age 64 years [IQR 58-68]) were enrolled and randomly assigned to the 54 Gy group (n=108) or 45 Gy (n=116) group. The median follow-up was 46 months (IQR 33-56). The median overall survival was significantly longer in the 54 Gy group (60·7 months [95% CI 49·2-62·0]) than in the 45 Gy group (39·5 months [27·5-51·4]; hazard ratio 0·55 [95% CI 0·37-0·72]; p=0·003). Treatment was tolerable, and the chemotherapy-related and radiotherapy-related toxicities were similar between the groups. The grade 3-4 radiotherapy toxicities were oesophagitis (14 [13%] of 108 patients in the 54 Gy group vs 14 [12%] of 116 patients in the 45 Gy group; p=0·84) and pneumonitis (five [5%] of 108 patients vs seven [6%] of 116 patients; p=0·663). Only one treatment-related death occurred in the 54 Gy group (myocardial infarction). The study was prematurely terminated by an independent data safety monitoring board on April 30, 2021, based on evidence of sufficient clinical benefit. INTERPRETATION: Compared with standard-dose thoracic radiotherapy (45 Gy), high-dose radiotherapy (54 Gy) improved overall survival without increasing toxicity in a cohort of patients aged 18-70 years with LS-SCLC. Our results support the use of twice-daily accelerated thoracic radiotherapy (54 Gy) with concurrent chemotherapy as an alternative first-line LS-SCLC treatment option. FUNDING: Chinese Society of Clinical Oncology-Linghang Cancer Research, the Wu Jieping Medical Foundation, and Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital and Beijing Municipal Administration of Hospitals Incubating Program.
引用
- Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024. PMID: 39146944. doi:10.1016/S2213-2600(24)00189-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。